Tenax Therapeutics Stock News

Tenax Therapeutics Inc (TENX) shares closed 2.3% lower than its previous 52 week low, giving the company a market cap of $20M. The stock is currently down 20.7% year-to-date, down 54.7% over the past 12 months, and down 98.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 23.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 134.3% The company's stock price performance over the past 12 months lags the peer average by 1476.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Tenax Therapeutics (TENX) announces that the USPTO has granted a patent for the companys subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for

Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible Extensions MORRISVILLE, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ: TENX ), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the company''s subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for the treatment of pulmonary hypertension associated with left heart failure (PH-HFpEF). On January 4, 2022, Tenax Therapeutics was issued US Pat. No. 11,213,524, entitled PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN , which is directed towards the use of levosimendan via subcutaneous administration for treating a subject having a health condition of any kind, such as heart failure, pulmonary hypertension including PH-HFpEF, chronic kidney disease, stroke, or other health conditions.

Tenax Therapeutics Inc (TENX) shares closed today 11.6% lower than it did at the end of yesterday. The stock is currently down 15.4% year-to-date, down 50.8% over the past 12 months, and down 98.1% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $1.46 and as low as $0.84 this week.Shares closed 76.1% below its 52-week high and 5.2% above its 52-week low.Trading volume this week was 272.1% higher than the 10-day average and 849.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 345.3% The company's stock price performance over the past 12 months lags the peer average by -1042.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Wall Street analysts expect Tenax Therapeutics, Inc. (NASDAQ:TENX) to report earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Tenax Therapeutics earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). Tenax Therapeutics reported earnings of ($0.60) per share during the same []

HC Wainwright reissued their buy rating on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note released on Friday, Price Targets.com reports. They currently have a $5.00 target price on the specialty pharmaceutical companys stock. Shares of TENX stock opened at $1.26 on Friday. The stock has a market capitalization of $31.76 million, a PE []

Tenax Therapeutics (NASDAQ:TENX) and Zosano Pharma (NASDAQ:ZSAN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. Profitability This table compares Tenax Therapeutics and Zosano Pharmas net margins, return on equity and []

Tenax Therapeutics (NASDAQ:TENX) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02), MarketWatch Earnings reports. TENX stock traded down $0.01 during midday trading on Thursday, hitting $1.33. The companys stock had a trading volume of 201 []

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the third quarter of 2021 and provided a business update. As we approach the new year, the Tenax team is building strong momentum across our lead clinical programs, said Christopher T. Giordano, Presiden

New York, New York--(Newsfile Corp. - July 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary

The stock price of Tenax Therapeutics Inc (NASDAQ: TENX) increased by over 12% pre-market. This is why it happened.

New York, New York--(Newsfile Corp. - June 7, 2021) -  Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.

The stock price of Tenax Therapeutics (NASDAQ: TENX) increased by over 35% during intraday trading. This is why it happened.